A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of KUR-101 in Healthy Adults

NCT ID: NCT05114265

Last Updated: 2022-12-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-02-15
• Study Completion Date: 2022-10-12

Brief Summary

This project is testing the safety, tolerability, pharmacokinetics (PK, the amount of study drug in your blood) and pharmacodynamics (PD, how the study drug affects your body) of single doses of a new drug called KUR-101.

Up to 58 healthy men or women aged between 18-55 will be enrolled in this study in two parts.

Part 1 will involve a single ascending (increasing) dose (SAD) where 40 participants (5 groups of 8) will be randomised (assigned randomly, like flipping a coin) to receive a single oral dose of the study drug or placebo. The placebo will look the same as the study drug but will not contain any medicine.

Part 2: will involve a crossover design where 18 participants will be randomised to receive a single oral dose of each of three interventions (study drug, placebo or a marketed form of oxycodone). Each dose is separated by 7 days and the participants are randomised so they do not know the order of the interventions.

For Part 1 the total participation will last 9 days, of which 4 days (3 nights) will be spent in the clinic. One group of subjects in Part 1 will return to the clinic to receive a second dose of drug given with a high fat breakfast. In this group, the total participation will last 16 days, of which 8 days (7 nights) will be spent in the clinic.

For Part 2 the total participation will last 23 days, of which 9 days (8 nights) will be spent in the clinic.

Detailed Description

This is a Phase 1, single-center, prospective, study of orally administered KUR-101 in normal healthy participants. The study will be conducted in two parts.

Part 1 is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, PK, analgesic and respiratory effects of single ascending doses of orally administered KUR-101 in normal healthy participants. Once the MTD has been determined, this dose, or an alternate lower dose, will be taken into Part 2 of the study.

Part 2 is a randomized, double-blind, placebo-controlled, three-period crossover study to assess the analgesic and respiratory effects of a single oral KUR-101 as compared to that of oxycodone in normal healthy participants.

Conditions

Acute Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Part 1: Single ascending dose

Single dose of oral KUR-101 or oral placebo

Group Type: EXPERIMENTAL

KUR-101

Intervention Type: DRUG

Single oral dose of KUR-101

Placebo

Intervention Type: DRUG

Single oral dose of placebo

Part 2: Three-way crossover

Single dose of oral KUR-101, oral placebo and oral OxyNorm

Group Type: EXPERIMENTAL

KUR-101

Intervention Type: DRUG

Single oral dose of KUR-101

OxyNorm

Intervention Type: DRUG

Single oral dose of OxyNorm

Placebo

Intervention Type: DRUG

Single oral dose of placebo

Interventions

KUR-101

Single oral dose of KUR-101

Intervention Type: DRUG

OxyNorm

Single oral dose of OxyNorm

Intervention Type: DRUG

Placebo

Single oral dose of placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy male and female subjects;
• Between 18 and 55 years of age;
• Provide a signed EC-approved consent form;
• Generally healthy, in the opinion of the Investigator;
• Body Mass Index (BMI) 18 to 32 kg/m^2;
• Using method of contraception;
• Willing and able to comply with protocol requirements for the duration of the study

Exclusion Criteria

• Subjects taking prohibited medications;
• Subjects with a history or presence of clinically significant medical or psychiatric disease;
• Subjects with a history of recreational or opiate use;
• Subjects with a history of alcohol abuse or moderate to severe substance abuse;
• Subjects who have regularly used nicotine-containing products;
• Subjects with a hospital admission or major illness within 1 month prior to Screening;
• Subjects with a major surgery within 3 months prior to Screening;
• Subjects who are pregnant or breastfeeding
• Subjects who have participated (taken investigative drug and/or device) in another clinical trial within 30 days prior to Screening;
• Subjects who belong to a vulnerable population.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Kures, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

KUR-101-101 Clinical Research Site

Christchurch, , New Zealand

Countries

New Zealand

Other Identifiers

KUR-101-101

Identifier Type: -

Identifier Source: org_study_id